Literature DB >> 22528740

Effects of antifungal agents alone and in combination against Candida glabrata strains susceptible or resistant to fluconazole.

Izabel Almeida Alves1, Laíssa Arévalo Bandeira, Débora Alves Nunes Mario, Laura Bedin Denardi, Louise Vignoles Neves, Janio Morais Santurio, Sydney Hartz Alves.   

Abstract

The rise of Candida spp. resistant to classic triazole antifungal agents has led to a search for new therapeutic options. Here, we evaluated combinations of antifungals in a checkerboard assay against two groups of Candida glabrata strains: one containing fluconazole-susceptible clinical isolates (FS) and another containing fluconazole-resistant laboratory derivative (FR). The most synergistic combination observed was amphotericin B + flucytosine (synergistic for 61.77 % of FS strains and 76.47 % of FR strains). The most antagonistic combination observed was ketoconazole + flucytosine (FS 61.77 % and FR 55.88 %). Surprisingly, most combinations evidenced indifferent interactions, and the best synergism appeared when amphotericin B and flucytosine were combined against both groups of isolates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528740     DOI: 10.1007/s11046-012-9538-7

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  28 in total

1.  Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.

Authors:  A Polak
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

2.  Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus.

Authors:  G Garcia-Effron; E Mellado; A Gomez-Lopez; L Alcazar-Fuoli; M Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine.

Authors:  V Dumaine; L Eyrolle; M T Baixench; A Paugam; F Larousserie; C Padoin; M Tod; D Salmon
Journal:  Int J Antimicrob Agents       Date:  2008-02-01       Impact factor: 5.283

4.  In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.

Authors:  F Barchiesi; D Gallo; F Caselli; L F Di Francesco; D Arzeni; A Giacometti; G Scalise
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

Review 5.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

6.  The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media.

Authors:  H Siau; D Kerridge
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

7.  Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans.

Authors:  R Arai; T Sugita; A Nishikawa
Journal:  Mycoses       Date:  2005-01       Impact factor: 4.377

8.  Caspofungin in combination with amphotericin B against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Annette W Fothergill; Daniela Arzeni; Gianfranco Greganti; Daniele Giannini; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.

Authors:  John E Bennett; Koichi Izumikawa; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more
  6 in total

1.  Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata.

Authors:  Laura Bedin Denardi; Débora Alves Nunes Mario; Erico Silva de Loreto; Cristina Wayne Nogueira; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2013-06-23       Impact factor: 2.574

2.  Commonly Used Oncology Drugs Decrease Antifungal Effectiveness against Candida and Aspergillus Species.

Authors:  Arielle Butts; Parker Reitler; Wenbo Ge; Jarrod R Fortwendel; Glen E Palmer
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1.

Authors:  Zoë Steier; John-Paul Vermitsky; Geoffrey Toner; Scott E Gygax; Thomas Edlind; Santosh Katiyar
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 4.  Multidrug resistance in fungi: regulation of transporter-encoding gene expression.

Authors:  Sanjoy Paul; W Scott Moye-Rowley
Journal:  Front Physiol       Date:  2014-04-16       Impact factor: 4.566

5.  Alginate oligosaccharides inhibit fungal cell growth and potentiate the activity of antifungals against Candida and Aspergillus spp.

Authors:  Anne Tøndervik; Håvard Sletta; Geir Klinkenberg; Charlotte Emanuel; Lydia C Powell; Manon F Pritchard; Saira Khan; Kieron M Craine; Edvar Onsøyen; Phil D Rye; Chris Wright; David W Thomas; Katja E Hill
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

6.  Pulmonary Candidiasis Associated with COVID-19: Evaluation of Causative Agents and their Antifungal Susceptibility Patterns.

Authors:  Fariba Shirvani; Azam Fattahi
Journal:  Tanaffos       Date:  2021-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.